Suppression of LPS-induced inflammatory responses by inflexanin B in BV2 microglial cells

Ji Youn Lim, Dong Geun Sul, Bang Yeon Hwang, Kwang Woo Hwang, Ki Yeol Yoo, So Young Park

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Microglia are a type of resident macrophage that functions as an inflammation modulator in the central nervous system. Over-activation of microglia by a range of stimuli disrupts the physiological homeostasis of the brain, and induces inflammatory response and degenerative processes, such as those implicated in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, we investigated the possible anti-inflammatory mechanisms of inflexanin B in murine microglial BV2 cells. Lipopolysaccharide (LPS) activated BV2 cells and induced the production of pro-inflammatory mediators such as nitric oxide (NO), prostaglandin E2 (PGE2), and cytokines (interleukins-1β and -6, and tumour necrosis factor α). The LPS-induced production of pro-inflammatory mediators was associated with the enhancement of nuclear factor-kappaB (NF-κB) nuclear translocation and the activation of mitogen-activated protein kinase (MAPK) including ERK1/2 and JNK. Conversely, pretreatment of cells with inflexanin B (10 and 20 μg/mL) significantly reduced the production of pro-inflammatory mediators. This was accompanied with the reduced nuclear translocation of NF-κB and reduced activation of MAPKs. These results suggest that inflexanin B attenuated the LPS-induced inflammatory process by inhibiting the activation of NF-κB and MAPKs.

Original languageEnglish
Pages (from-to)141-148
Number of pages8
JournalCanadian Journal of Physiology and Pharmacology
Volume91
Issue number2
DOIs
Publication statusPublished - 2013 Feb 1

Fingerprint

Lipopolysaccharides
Microglia
Mitogen-Activated Protein Kinases
Interleukin-1
Dinoprostone
Neurodegenerative Diseases
Parkinson Disease
Interleukin-6
Alzheimer Disease
Nitric Oxide
Homeostasis
Anti-Inflammatory Agents
Central Nervous System
Tumor Necrosis Factor-alpha
Macrophages
Cytokines
Inflammation
Brain
inflexanin B

Keywords

  • Anti-inflammatory effect
  • Inflexanin B
  • Microglial cells
  • NF- and κB

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)
  • Pharmacology

Cite this

Suppression of LPS-induced inflammatory responses by inflexanin B in BV2 microglial cells. / Lim, Ji Youn; Sul, Dong Geun; Hwang, Bang Yeon; Hwang, Kwang Woo; Yoo, Ki Yeol; Park, So Young.

In: Canadian Journal of Physiology and Pharmacology, Vol. 91, No. 2, 01.02.2013, p. 141-148.

Research output: Contribution to journalArticle

Lim, Ji Youn ; Sul, Dong Geun ; Hwang, Bang Yeon ; Hwang, Kwang Woo ; Yoo, Ki Yeol ; Park, So Young. / Suppression of LPS-induced inflammatory responses by inflexanin B in BV2 microglial cells. In: Canadian Journal of Physiology and Pharmacology. 2013 ; Vol. 91, No. 2. pp. 141-148.
@article{3a52a75802f2448aaf5927c7846bfced,
title = "Suppression of LPS-induced inflammatory responses by inflexanin B in BV2 microglial cells",
abstract = "Microglia are a type of resident macrophage that functions as an inflammation modulator in the central nervous system. Over-activation of microglia by a range of stimuli disrupts the physiological homeostasis of the brain, and induces inflammatory response and degenerative processes, such as those implicated in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, we investigated the possible anti-inflammatory mechanisms of inflexanin B in murine microglial BV2 cells. Lipopolysaccharide (LPS) activated BV2 cells and induced the production of pro-inflammatory mediators such as nitric oxide (NO), prostaglandin E2 (PGE2), and cytokines (interleukins-1β and -6, and tumour necrosis factor α). The LPS-induced production of pro-inflammatory mediators was associated with the enhancement of nuclear factor-kappaB (NF-κB) nuclear translocation and the activation of mitogen-activated protein kinase (MAPK) including ERK1/2 and JNK. Conversely, pretreatment of cells with inflexanin B (10 and 20 μg/mL) significantly reduced the production of pro-inflammatory mediators. This was accompanied with the reduced nuclear translocation of NF-κB and reduced activation of MAPKs. These results suggest that inflexanin B attenuated the LPS-induced inflammatory process by inhibiting the activation of NF-κB and MAPKs.",
keywords = "Anti-inflammatory effect, Inflexanin B, Microglial cells, NF- and κB",
author = "Lim, {Ji Youn} and Sul, {Dong Geun} and Hwang, {Bang Yeon} and Hwang, {Kwang Woo} and Yoo, {Ki Yeol} and Park, {So Young}",
year = "2013",
month = "2",
day = "1",
doi = "10.1139/cjpp-2012-0242",
language = "English",
volume = "91",
pages = "141--148",
journal = "Canadian Journal of Physiology and Pharmacology",
issn = "0008-4212",
publisher = "National Research Council of Canada",
number = "2",

}

TY - JOUR

T1 - Suppression of LPS-induced inflammatory responses by inflexanin B in BV2 microglial cells

AU - Lim, Ji Youn

AU - Sul, Dong Geun

AU - Hwang, Bang Yeon

AU - Hwang, Kwang Woo

AU - Yoo, Ki Yeol

AU - Park, So Young

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Microglia are a type of resident macrophage that functions as an inflammation modulator in the central nervous system. Over-activation of microglia by a range of stimuli disrupts the physiological homeostasis of the brain, and induces inflammatory response and degenerative processes, such as those implicated in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, we investigated the possible anti-inflammatory mechanisms of inflexanin B in murine microglial BV2 cells. Lipopolysaccharide (LPS) activated BV2 cells and induced the production of pro-inflammatory mediators such as nitric oxide (NO), prostaglandin E2 (PGE2), and cytokines (interleukins-1β and -6, and tumour necrosis factor α). The LPS-induced production of pro-inflammatory mediators was associated with the enhancement of nuclear factor-kappaB (NF-κB) nuclear translocation and the activation of mitogen-activated protein kinase (MAPK) including ERK1/2 and JNK. Conversely, pretreatment of cells with inflexanin B (10 and 20 μg/mL) significantly reduced the production of pro-inflammatory mediators. This was accompanied with the reduced nuclear translocation of NF-κB and reduced activation of MAPKs. These results suggest that inflexanin B attenuated the LPS-induced inflammatory process by inhibiting the activation of NF-κB and MAPKs.

AB - Microglia are a type of resident macrophage that functions as an inflammation modulator in the central nervous system. Over-activation of microglia by a range of stimuli disrupts the physiological homeostasis of the brain, and induces inflammatory response and degenerative processes, such as those implicated in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, we investigated the possible anti-inflammatory mechanisms of inflexanin B in murine microglial BV2 cells. Lipopolysaccharide (LPS) activated BV2 cells and induced the production of pro-inflammatory mediators such as nitric oxide (NO), prostaglandin E2 (PGE2), and cytokines (interleukins-1β and -6, and tumour necrosis factor α). The LPS-induced production of pro-inflammatory mediators was associated with the enhancement of nuclear factor-kappaB (NF-κB) nuclear translocation and the activation of mitogen-activated protein kinase (MAPK) including ERK1/2 and JNK. Conversely, pretreatment of cells with inflexanin B (10 and 20 μg/mL) significantly reduced the production of pro-inflammatory mediators. This was accompanied with the reduced nuclear translocation of NF-κB and reduced activation of MAPKs. These results suggest that inflexanin B attenuated the LPS-induced inflammatory process by inhibiting the activation of NF-κB and MAPKs.

KW - Anti-inflammatory effect

KW - Inflexanin B

KW - Microglial cells

KW - NF- and κB

UR - http://www.scopus.com/inward/record.url?scp=84874594801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874594801&partnerID=8YFLogxK

U2 - 10.1139/cjpp-2012-0242

DO - 10.1139/cjpp-2012-0242

M3 - Article

VL - 91

SP - 141

EP - 148

JO - Canadian Journal of Physiology and Pharmacology

JF - Canadian Journal of Physiology and Pharmacology

SN - 0008-4212

IS - 2

ER -